Articles related to OVARIAN CANCER

Dr. Janos Tanyi, Associate Professor of Obstetrics and Gynecology at the Hospital of the University of Pennsylvania, is joined by Dr. Charles Turck to discuss fluorescence-guided, intraoperative imaging as well as a new imaging drug to help physicians better detect ovarian cancer.

This phase III trial evaluated the PARP inhibitor fuzuloparib versus placebo as a maintenance treatment after second- or later-line platinum-based chemotherapy in patients with high-grade, platinum-sensitive, recurrent ovarian cancer. Two-hundred-fifty-two (252) patients were randomly assigned to the fuzuloparib (n = 167) or placebo (n = 85). Twice daily oral fuzuloparib as maintenance therapy was superior to placebo in PFS improvement. Further, benefit was observed both in patients with germline BRCA 1/2 mutations and in those without mutations.

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

Blocking expression of FOXK2 in cancer stem cells inhibited growth of these cells, reducing their so-called “stemness,” making them more like normal cells.

Mirvetuximab soravtansine generated an objective response in nearly 1/3 of patients participating. That compares with response rates in the single digits for current treatments in patients whose ovarian cancer doesn’t respond to platinum-based chemotherapy.

This editorial reflects on the work by Lei and colleagues in teasing out hrHPV-negative vs. positive ovarian cancers with a 15-year follow up. But what to do with the knowledge?